𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells

✍ Scribed by Yuko Yonezawa; Yoji Nagashima; Hiromi Sato; Nantiga Virgona; Keiko Fukumoto; Sumiko Shirai; Hiromi Hagiwara; Taiichiro Seki; Toyohiko Ariga; Hironobu Senba; Kazuyuki Suzuki; Ryuji Asano; Kiyokazu Hagiwara; Tomohiro Yano


Publisher
John Wiley and Sons
Year
2005
Tongue
English
Weight
324 KB
Volume
43
Category
Article
ISSN
0899-1987

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Although the constitute activation of the Src family of kinases (Src) has been established as a poor prognostic factor in several types of cancer, the role of Src in renal cell carcinoma (RCC) has not been defined. This study aimed to determine whether Src could contribute to the appearance of malignant phenotypes in RCC. The role of Src in the appearance of malignant phenotypes in RCC was examined in two human renal cancer cell lines, Caki‐1 from human metastatic RCC and ACHN from human primary RCC. Src activity in Caki‐1 cells was higher than that in ACHN cells, and this difference corresponded to the difference of PP1 (a Src family inhibitor)‐induced cytotoxicity on the two cells. The difference in cytotoxicity between the cells did not depend on cell cycle regulation but on the induction of apoptosis, and the difference in apoptosis particularly related to the reduction of the Bcl‐xL level. Furthermore, in Caki‐1 cells with higher Src activity, Src stimulated the production of vascular endothelial growth factor (VEGF), partially via the activation of Stat3, and the inhibition of Src activity caused a reduction of the VEGF level in serum, angiogenesis, and tumor development in a xenograft model. These results suggested that Src contributed to the appearance of malignant phenotypes in renal cancer cells, particularly due to the resistance against apoptosis by Bcl‐xL and angiogenesis stimulated by Src‐Stat3‐VEGF signaling. © 2005 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Annexin A2 positively contributes to the
✍ Junichi Inokuchi; Navneet Narula; David S. Yee; Douglas W. Skarecky; Alice Lau; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 French ⚖ 421 KB

## Abstract Several groups, including ours, have reported that annexin A2 (ANXA2) expression is reduced in most prostate cancer (CaP). More recently, however, we reported that ANXA2 is expressed in some high‐grade tumors, but the biologic consequence of this is currently unknown. To elucidate the f

Cell-surface sulfoglycolipids are involv
✍ Takahiko Kobayashi; Koichi Honke; Yasuhiro Kuramitsu; Masuo Hisokawa; Tamotsu Mi 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 885 KB

We investigated the role of sulfoglycolipids on human renalcell carcinoma cells (SMKT-R3) in the attachment to a substrate adhesive protein, laminin. SMKT-R3 cells over-express sulfoglycolipids, including SM2, SM3 and SM4. When acidic glycolipid fractions were extracted from SMKT-R3 cells, separated

Functional p53 in cells contributes to t
✍ Martina Paprskářová; Vladimír Kryštof; Radek Jorda; Petr Džubák; Marián Hajdúch; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB

## Abstract Inhibitors of cyclin‐dependent kinases (CDKs) undergoing clinical trials as anticancer agents usually target several CDKs in cells. Some of them are also able to increase cellular levels of p53 protein and to activate p53‐regulated transcription. To define the role of p53 in the antican